Literature DB >> 35450373

Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols.

Arvin M Gouw1, Vineet Kumar2, Angel Resendez2, Fidelia B Alvina1, Natalie S Liu1, Katherine Margulis3, Ling Tong1, Richard N Zare3, Sanjay V Malhotra2,4,5, Dean W Felsher1.   

Abstract

A natural compound screen identified several anticancer compounds, among which azapodophyllotoxin (AZP) was found to be the most potent. AZP caused decreased viability of both mouse and human lymphoma and renal cell cancer (RCC) tumor-derived cell lines. Novel AZP derivatives were synthesized and screened identifying compound NSC750212 to inhibit the growth of both lymphoma and RCC both in vitro and in vivo. A nanoimmunoassay was used to assess the NSC750212 mode of action in vivo. On the basis of the structure of AZP and its mode of action, AZP disrupts tubulin polymerization. Through desorption electrospray ionization mass spectrometry imaging, NSC750212 was found to inhibit lipid metabolism. NSC750212 suppresses monoglycerol metabolism depleting lipids and thereby inhibits tumor growth. The dual mode of tubulin polymerization disruption and monoglycerol metabolism inhibition makes NSC750212 a potent small molecule against lymphoma and RCC.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35450373      PMCID: PMC9014495          DOI: 10.1021/acsmedchemlett.1c00673

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  40 in total

Review 1.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

Review 2.  The re-emergence of natural products for drug discovery in the genomics era.

Authors:  Alan L Harvey; RuAngelie Edrada-Ebel; Ronald J Quinn
Journal:  Nat Rev Drug Discov       Date:  2015-01-23       Impact factor: 84.694

Review 3.  Counting on natural products for drug design.

Authors:  Tiago Rodrigues; Daniel Reker; Petra Schneider; Gisbert Schneider
Journal:  Nat Chem       Date:  2016-04-25       Impact factor: 24.427

4.  Nonenolizable podophyllotoxin derivatives.

Authors:  W J Gensler; C D Murthy; M H Trammell
Journal:  J Med Chem       Date:  1977-05       Impact factor: 7.446

5.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Authors:  Emelyn H Shroff; Livia S Eberlin; Vanessa M Dang; Arvin M Gouw; Meital Gabay; Stacey J Adam; David I Bellovin; Phuoc T Tran; William M Philbrick; Adolfo Garcia-Ocana; Stephanie C Casey; Yulin Li; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

Review 6.  Cellular fatty acid metabolism and cancer.

Authors:  Erin Currie; Almut Schulze; Rudolf Zechner; Tobias C Walther; Robert V Farese
Journal:  Cell Metab       Date:  2013-06-20       Impact factor: 27.287

Review 7.  Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer.

Authors:  Marteinn Thor Snaebjornsson; Sudha Janaki-Raman; Almut Schulze
Journal:  Cell Metab       Date:  2019-12-05       Impact factor: 27.287

8.  Discovery of podophyllotoxins.

Authors:  T F Imbert
Journal:  Biochimie       Date:  1998-03       Impact factor: 4.079

Review 9.  Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells.

Authors:  Qiuyan Guo; Enshe Jiang
Journal:  Curr Top Med Chem       Date:  2021       Impact factor: 3.295

Review 10.  Emerging roles of lipid metabolism in cancer metastasis.

Authors:  Xiangjian Luo; Can Cheng; Zheqiong Tan; Namei Li; Min Tang; Lifang Yang; Ya Cao
Journal:  Mol Cancer       Date:  2017-04-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.